Bronx Zip Population and Density

2010 Census Data on population, pop density, age and ethnicity per zip code

Public Transit Services and Reduced-fare Programs by County, Current, Transportation

This dataset lists all public transit services and reduced-fare programs currently provided in each county of PA. Public transportation is available in every county in Pennsylvania, with a wide range of services including: - Fixed-route transit service in Philadelphia, Pittsburgh, 21 small urban areas, and 22 rural areas - 44 systems offering shared-ride services in all Pennsylvania counties - 13 intercity bus routes - Keystone Corridor Amtrak service, running from Harrisburg to New York by way of Philadelphia, and Pennsylvanian Amtrak service running from Pittsburgh to Philadelphia - 66 counties with rural transportation for persons with disabilities NOTE: Service providers offering two or more reduced-fare programs have duplicate records to reflect the various programs and to allow sorting by program type.

Delinquency Dispositions CY 2014 - Current Statewide as Reported by the Juvenile Court Judges' Commission

There were 22,023 delinquency dispositions in Pennsylvania during 2018. This represents a 1.3% decrease from 2017 and a 13.4% decrease since 2014. Allegheny County reported a decrease of 17.0% from 2017 to 2018, and Philadelphia County reported a 5.9% decrease for this time period. One-third of the total dispositions occurred in the four jurisdictions reporting more than 1,000 dispositions; these jurisdictions include Philadelphia, Allegheny, York, and Delaware. This dataset is contained within the Juvenile Court Judges' Commissions 2018 Juvenile Court Annual Report; this report provides an overview of Pennsylvania juvenile court statistics, during 2018 and preceding years, to measure and quantify work across the state by juvenile justice professionals. In Pennsylvania, juvenile court jurisdiction extends over individuals who have been alleged to have committed a delinquent act, as defined by 42. Pa. C. S. § 6301 et seq., on or after their tenth birthday and prior to reaching eighteen years of age. Juvenile court supervision can extend until the individual is twenty-one years of age if the individual is currently under supervision. Age for purposes of this section was calculated from the juvenile’s date of birth to the date of the offense in the written allegation.

Refrigerated Truck Rates and Availability

Data from AMS Market News Specialty Crops Program, including weekly refrigerated truck rates and availability by origin, destination, and commodity. The Transportation Services Division assigns a broader region to the origins in order to join to refrigerated truck rate and availability data.

Delinquency Dispositions CY 2014 - Current By County as Reported by the Juvenile Court Judges' Commission

This dataset represents the total number of delinquency dispositions processed by Pennsylvania juvenile courts in 2018. A disposition is defined as an allegation of delinquency disposed of by the juvenile probation department and/or the court. This dataset is contained within the Juvenile Court Judges' Commission’s Calendar Year (CY) 2018 Juvenile Court Annual Report; this report provides an overview of Pennsylvania juvenile court statistics, during 2018, to measure and quantify work across the state by juvenile justice professionals. In Pennsylvania, juvenile court jurisdiction extends over individuals who have been alleged to have committed a delinquent act, as defined by 42. Pa. C. S. § 6301 et seq., on or after their tenth birthday and prior to reaching eighteen years of age. Juvenile court supervision can extend until the individual is twenty-one years of age if the individual is currently under supervision. Age for purposes of this section was calculated from the juvenile’s date of birth to the date of the offense in the written allegation. Any one youth may be involved in a number of dispositions within a calendar year containing multiple allegations. There were 22,023 delinquency dispositions in Pennsylvania during 2018. This represents a 1.3% decrease from 2017 and a 13.4% decrease since 2014. Allegheny County reported a decrease of 17.0% from 2017 to 2018, and Philadelphia County reported a 5.9% decrease for this time period. One-third of the total dispositions occurred in the four jurisdictions reporting more than 1,000 dispositions; these jurisdictions include Philadelphia, Allegheny, York, and Delaware.

Individuals under Medical Assistance (Newly Eligible) Diagnosed with Opioid Use Disorder CY 2015-Current Annual County Human Services

This dataset contains the total counts of PA Department of Human Services (DHS) Medical Assistance (MA) individuals diagnosed with Opioid Use Disorder (OUD) or OUD Poisoning. Also included are individuals receiving MAT (Medication assisted treatment - the use of medications in combination with counseling and behavioral therapies for the treatment of substance use disorders.) NOT diagnosed in the same period. Limited to the Newly Eligible (Under the Medical Assistance Expansion Program. Find more information here: http://www.dhs.pa.gov/cs/groups/webcontent/documents/document/c_257436.pdf) segment of DHS population. Internally defined as DHS Category of Assistance = MG (Modified Adjusted Gross Income - MAGI) MG and Program Status = 91 (Newly Eligible). Counts are reported by Pennsylvania case county and covers calendar years 2015 -2018.

MUNICIPAL_BOUNDARY

Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Booster Dose

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

County to CBSA Mapping for Large Metros

Data contains counties in the following list of CBSAS (per OMB Mar 2020 definition): Bay Area CBSAs: San Francisco-Oakland-Berkeley, CA San Jose-Sunnyvale-Santa Clara, CA Napa, CA Santa Rosa-Petaluma, CA Other CBSAs: Los Angeles-Long Beach-Anaheim, CA Washington-Arlington-Alexandria, DC-VA-MD-WV Denver-Aurora-Lakewood, CO Detroit-Warren-Dearborn, MI Philadelphia-Camden-Wilmington, PA-NJ-DE-MD Boston-Cambridge-Newton, MA-NH New York-Newark-Jersey City, NY-NJ-PA Phoenix-Mesa-Chandler, AZ Houston-The Woodlands-Sugar Land, TX Seattle-Tacoma-Bellevue, WA Atlanta-Sandy Springs-Alpharetta, GA Chicago-Naperville-Elgin, IL-IN-WI Austin-Round Rock-Georgetown, TX Dallas-Fort Worth-Arlington, TX Miami-Fort Lauderdale-Pompano Beach, FL